
\begin{table}[htbp]
\centering
\caption{Robustness Checks}
\label{tab:robustness}
\begin{tabular}{lccccc}
\toprule
Specification & ATT & SE & $p$-value & $N$ & States \\
\midrule
\multicolumn{6}{l}{\textit{Panel A: Alternative Specifications}} \\[3pt]
Baseline CS-DiD (not-yet-treated) & 0.112 & 0.097 & 0.251 & 918 & 51 \\
Region $\times$ Year FE (TWFE) & 0.001 & 0.057 & 0.980 & 918 & 51 \\
Log electricity employment & 0.106 & 0.096 & 0.268 & 918 & 51 \\
Alt.\ treatment (target $>$ 5\%) & 0.131 & 0.106 & 0.213 & 918 & 51 \\
Late-adopter cohorts ($g \geq 2008$) & 0.056 & 0.118 & 0.632 & 918 & 51 \\
Excl.\ borderline states & 0.107 & 0.111 & 0.336 & 918 & 51 \\
Excl.\ VA \& WV from controls & 0.108 & 0.109 & 0.321 & 882 & 49 \\[6pt]
\multicolumn{6}{l}{\textit{Panel B: Placebo Outcomes}} \\[3pt]
Manufacturing employment & 4.837 & 2.962 & 0.102 & 918 & 51 \\
Total employment & 7.406 & 7.826 & 0.344 & 918 & 51 \\
\bottomrule
\end{tabular}
\begin{tablenotes}[flushleft]
\footnotesize
\item \textit{Notes:} All specifications use the Callaway-Sant'Anna (2021) doubly-robust estimator with not-yet-treated comparison group unless otherwise noted. Standard errors computed via multiplier bootstrap (1,000 iterations), clustered at the state level. The dependent variable is electricity sector employment per 1,000 total population unless otherwise indicated. ``Region $\times$ Year FE'' adds Census region-by-year fixed effects to the TWFE specification. ``Alt.\ treatment'' redefines the treatment indicator to require an RPS target exceeding 5\% of retail sales. ``Late-adopter cohorts'' aggregates the CS-DiD ATT over cohorts first treated in 2008 or later (the full panel is retained; only the aggregation changes). ``Excl.\ borderline states'' reclassifies four states with potentially voluntary or non-binding standards (LA, ND, SC, UT) as untreated, yielding 31 treated states. ``Excl.\ VA \& WV'' drops Virginia (VCEA 2020 contaminates control) and West Virginia (AREPS 2009--2015) from the sample entirely ($N = 49 \times 18 = 882$). Placebo outcomes should show null effects if RPS specifically affects the electricity sector.
\end{tablenotes}
\end{table}

